Older women now have a new option for the prevention of breast cancer. Raloxifene (which is already on the market as the osteoporosis drug Evista) has been approved by the FDA to reduce breast cancer risk.
Researchers have been noticing that women on Evista have had a lower rate of breast cancer than the general population. It is now believed that it could block estrogen receptors in the breast and therefore possibly prevent invasive breast cancer.
The ideal patients for this use of reloxifene are postmenopausal women who are already at high risk for breast cancer, and those who have osteoporosis. As for younger women whose doctors have deemed at high risk for breast cancer, reloxifene’s preventative ability and safety hasn’t been studied yet. Tamoxifen remains the drug of choice for this group.
Find a Doctor
Find a NewBeauty "Top Beauty Doctor" Near you